Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Hemoglobin and Methemoglobin
- Normal oxygen transport
- Methemoglobinemia: two pronged attack
- O2-Hemoglobin dissociation curve
- Methemoglobinemia and cyanosis
- Methemoglobin reduction
- Methemoglobinemia: chronic / acute-toxic
- Causes of methemoglobinemia
- CytB5R gene - structure
- Cytochrome b5 reductase (Cytb5R)
- Cytb5R amino acid sequence
- Cytb5R deficiency type I
- Cytb5R deficiency type II
- Cytb5R deficiency type I vs. type II
- Mutations of CYB5R gene
- Cytochrome b5 reductase deficiency distribution
- Differential diagnosis of methemoglobinemia
- Methemoglobin reduction: 3 pathways
- Methemoglobinemia therapy
- Methemoglobinemia therapy summary
- Acknowledgements
Topics Covered
- Formation of methemoglobinemia
- Review of methemoglobinemias types
- Cytochrome b5 reductase (Cytb5 R)
- Mutations and clinical phenotypes of Cytb5 R deficiency
- Differential diagnosis from other methemoglobinemias
- Therapy of methemoglobinemia
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Reading, S. (2018, February 27). Cytochrome b5 reductase deficiency and hereditary methemoglobinemia [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/LXWO7513.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Scott Reading has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Scott Reading.
I'm an Adjunct Assistant Professor in
the Department of Pathology in Division of Hematology at the University of Utah
and an investigator at
ARUP Laboratories Institute for Clinical and Experimental Pathology
in Salt Lake City Utah.
The topic of this presentation is
Cytochrome b5 Reductase Deficiency as it relates to Hereditary Methemoglobinemia.
0:25
I will be following this outline for the presentation.
I'll briefly review how Methemoglobin is formed and discuss
how it interferes with the proper transport of oxygen in the body.
I will then introduce different causes of Methemoglobinemia and discuss
in detail the role of Cytochrome b5 reductase in this disorder.
This discussion will illustrate two clinical phenotypes and outline what is known
about the various mutations and how they can
change the function of this important enzyme.
Next, I will discuss the differential diagnosis of Methemoglobinemia caused by
Cytochrome b5 reductase deficiency and contrast this with
other types of Methemoglobinemia caused by genetic or acquired conditions.
In closing, I will discuss suggested therapies for Methemoglobinemia.
1:10
To understand the origin of Methemoglobin,
we must start with Hemoglobin.
Hemoglobin is the principal component of red blood cells
responsible for carrying oxygen from the lungs to the tissues.
It is a tetrameric protein complex composed of four globin subunits.
At the center of each globin subunit is
a ferrous iron containing porphyryn ring co-factor called heme.
The ferrous iron binds molecular oxygen from the lungs
converting the ferro-deoxyhemoglobin to ferry-oxyhemoglobin.
Methaemoglobin is an altered state of Hemoglobin.
This occurs when the ferrous iron of
heme in deoxyhemoglobin is oxidized to the ferric state.
In the ferric state, the iron is no longer able to bind molecular oxygen.
In addition, as Hemoglobin is a tetrameric protein with four globin subunits,
when one of these globin subunit hemes is converted to the ferric state.
It affects the other ferrous hemes to have a greater affinity for oxygen.
That result is a decreased ability of
that Hemoglobin molecule to deliver oxygen to the tissues.